DATE: September 15, 2020
TIME: 08:00am PT
Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existing therapies but is also very much a focus area in the development of new therapeutics. Flow cytometry–based experiments to characterize the TIME allow analysis of up to 40 markers per run; however, they lack any information on spatial distribution and cellular interactions. Conversely, classical fluorescence microscopy–based approaches provide spatial information but only allow the analysis of a maximum of 10 markers per sample. Even novel image-based multiplexing technologies are not able to provide insights that go much deeper than high-end flow cytometric options with respect to the number of markers. MICS technology is based on innovative use of next-generation cyclic immunofluorescence staining, and overcomes these drawbacks by using an iterative staining and erasing process, which allows for the analysis of 100+ markers on a single sample, whilst retaining that critical information on special distribution and cellular interactions. Stefan Eulitz, Global Customer Liaison Manager and former Deputy Development Program Leader of the MACSima™ Imaging Platform at Miltenyi Biotec, will show how MICS technology has ushered in a new era in high content imaging – ultra high content imaging, whilst providing insights into the analysis of the TIME in different tumor samples in an unrivaled depth.
- Define the optimal number of markers for characterization of the TIME
- Review MICS technology for next generation cyclic immunofluorescence staining
- Analyze the tumor immune microenvironment using ultra high content imaging
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.